07.11.2023 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023. “Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by .
Operator: Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The maternal RSV vaccine will significantly reduce infant hospitalizations and curb medical costs, finds a new modeling study exploring the benefit of widespread use.
Wastewater monitoring is an established tool for tracking COVID, and now new evidence shows it can be used alongside clinical testing to assess the burden of influenza and RSV in communities.